140 related articles for article (PubMed ID: 12871083)
1. Hypoxic radiosensitizers and hypoxic cytotoxins in radiation oncology.
Weinmann M; Welz S; Bamberg M
Curr Med Chem Anticancer Agents; 2003 Sep; 3(5):364-74. PubMed ID: 12871083
[TBL] [Abstract][Full Text] [Related]
2. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
[TBL] [Abstract][Full Text] [Related]
3. Ferroptosis: Frenemy of Radiotherapy.
Kerkhove L; Geirnaert F; Dufait I; De Ridder M
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612455
[TBL] [Abstract][Full Text] [Related]
4. Application of Radiosensitizers in Cancer Radiotherapy.
Gong L; Zhang Y; Liu C; Zhang M; Han S
Int J Nanomedicine; 2021; 16():1083-1102. PubMed ID: 33603370
[TBL] [Abstract][Full Text] [Related]
5. Design of antiangiogenic hypoxic cell radiosensitizers: 2-nitroimidazoles containing a 2-aminomethylene-4-cyclopentene-1,3-dione moiety.
Uto Y; Nagasawa H; Jin CZ; Nakayama S; Tanaka A; Kiyoi S; Nakashima H; Shimamura M; Inayama S; Fujiwara T; Takeuchi Y; Uehara Y; Kirk KL; Nakata E; Hori H
Bioorg Med Chem; 2008 Jun; 16(11):6042-53. PubMed ID: 18474428
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia: a barricade to conquer the pancreatic cancer.
Tan Z; Xu J; Zhang B; Shi S; Yu X; Liang C
Cell Mol Life Sci; 2020 Aug; 77(16):3077-3083. PubMed ID: 31907561
[TBL] [Abstract][Full Text] [Related]
7.
Busk M; Eggertsen PP; Overgaard J; Horsman MR; Tørring T; Jacobsen KM; Poulsen TB
Anticancer Res; 2023 Dec; 43(12):5319-5329. PubMed ID: 38030202
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic application of manganese-based nanosystems in cancer radiotherapy.
Pan S; Sun Z; Zhao B; Miao L; Zhou Q; Chen T; Zhu X
Biomaterials; 2023 Nov; 302():122321. PubMed ID: 37722183
[TBL] [Abstract][Full Text] [Related]
9. Tumor hypoxia: a target for selective cancer therapy.
Kizaka-Kondoh S; Inoue M; Harada H; Hiraoka M
Cancer Sci; 2003 Dec; 94(12):1021-8. PubMed ID: 14662015
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical Considerations of Tumor Selective Drug Delivery and Activity Confinement with Particular Reference to 1,2-Bis(Sulfonyl)-1- Alkylhydrazines Delivery.
Penketh P; Williamson H; Shyam K
Curr Drug Deliv; 2020; 17(5):362-374. PubMed ID: 32342817
[TBL] [Abstract][Full Text] [Related]
11. Strategies based on metal-based nanoparticles for hypoxic-tumor radiotherapy.
Zhang C; Yan L; Gu Z; Zhao Y
Chem Sci; 2019 Aug; 10(29):6932-6943. PubMed ID: 31588260
[TBL] [Abstract][Full Text] [Related]
12. Imageable Biomarkers for Radiotherapy Response.
Woliner-van der Weg W; Span PN; Braam PM; Bussink J
Prog Tumor Res; 2017; 44():11-24. PubMed ID: 38243419
[TBL] [Abstract][Full Text] [Related]
13. Chemical radiosensitizers for use in radiotherapy.
Wardman P
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
[TBL] [Abstract][Full Text] [Related]
14. Hypoxic radiosensitization: adored and ignored.
Overgaard J
J Clin Oncol; 2007 Sep; 25(26):4066-74. PubMed ID: 17827455
[TBL] [Abstract][Full Text] [Related]
15. The dose-rate effect revisited: radiobiological considerations of importance in radiotherapy.
Hall EJ; Brenner DJ
Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1403-14. PubMed ID: 1938548
[TBL] [Abstract][Full Text] [Related]
16. The impact of hypoxia and its modification of the outcome of radiotherapy.
Horsman MR; Overgaard J
J Radiat Res; 2016 Aug; 57 Suppl 1(Suppl 1):i90-i98. PubMed ID: 26983987
[TBL] [Abstract][Full Text] [Related]
17. Radio-Sensitizing Effects of Cu
Nandy P; Mukherjee A; Pradhan C; Das S
ACS Omega; 2020 Oct; 5(40):25668-25676. PubMed ID: 33073092
[TBL] [Abstract][Full Text] [Related]
18. Electron Ionization of Imidazole and Its Derivative 2-Nitroimidazole.
Meißner R; Feketeová L; Ribar A; Fink K; Limão-Vieira P; Denifl S
J Am Soc Mass Spectrom; 2019 Dec; 30(12):2678-2691. PubMed ID: 31667709
[TBL] [Abstract][Full Text] [Related]
19. The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption.
Yasui H; Asanuma T; Kino J; Yamamori T; Meike S; Nagane M; Kubota N; Kuwabara M; Inanami O
BMC Cancer; 2013 Mar; 13():106. PubMed ID: 23496909
[TBL] [Abstract][Full Text] [Related]
20. Development of hypoxia enhanced 111In-labeled Bombesin conjugates: design, synthesis, and in vitro evaluation in PC-3 human prostate cancer.
Wagh NK; Zhou Z; Ogbomo SM; Shi W; Brusnahan SK; Garrison JC
Bioconjug Chem; 2012 Mar; 23(3):527-37. PubMed ID: 22296619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
